These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 38364553)
1. Symptom clusters in adolescent depression and differential responses of clusters to pharmacologic treatment. Kim KM; Lee KH; Kim H; Kim O; Kim JW J Psychiatr Res; 2024 Apr; 172():59-65. PubMed ID: 38364553 [TBL] [Abstract][Full Text] [Related]
2. Symptom clusters in adolescent depression and differential response to treatment: a secondary analysis of the Treatment for Adolescents with Depression Study randomised trial. Bondar J; Caye A; Chekroud AM; Kieling C Lancet Psychiatry; 2020 Apr; 7(4):337-343. PubMed ID: 32199509 [TBL] [Abstract][Full Text] [Related]
3. Reevaluating the Efficacy and Predictability of Antidepressant Treatments: A Symptom Clustering Approach. Chekroud AM; Gueorguieva R; Krumholz HM; Trivedi MH; Krystal JH; McCarthy G JAMA Psychiatry; 2017 Apr; 74(4):370-378. PubMed ID: 28241180 [TBL] [Abstract][Full Text] [Related]
4. Baseline severity of depression predicts antidepressant drug response relative to escitalopram. Kilts CD; Wade AG; Andersen HF; Schlaepfer TE Expert Opin Pharmacother; 2009 Apr; 10(6):927-36. PubMed ID: 19317630 [TBL] [Abstract][Full Text] [Related]
5. New generation antidepressants for depression in children and adolescents: a network meta-analysis. Hetrick SE; McKenzie JE; Bailey AP; Sharma V; Moller CI; Badcock PB; Cox GR; Merry SN; Meader N Cochrane Database Syst Rev; 2021 May; 5(5):CD013674. PubMed ID: 34029378 [TBL] [Abstract][Full Text] [Related]
6. Letter to the Editor: CONVERGENCES AND DIVERGENCES IN THE ICD-11 VS. DSM-5 CLASSIFICATION OF MOOD DISORDERS. Cerbo AD Turk Psikiyatri Derg; 2021; 32(4):293-295. PubMed ID: 34964106 [TBL] [Abstract][Full Text] [Related]
7. [Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder]. Azorin JM; Llorca PM; Despiegel N; Verpillat P Encephale; 2004; 30(2):158-66. PubMed ID: 15107719 [TBL] [Abstract][Full Text] [Related]
8. Psychometric Properties and Factor Structures of the Korean Version of Children's Depression Rating Scale-Revised. Kim KM; Nam S; Choi JW; Jung AH; Hong SB; Kim JW; Kim SY; Kim E; Kim JW J Child Adolesc Psychopharmacol; 2018 May; 28(4):285-292. PubMed ID: 28771381 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of a Machine Learning Model Based on Pretreatment Symptoms and Electroencephalographic Features to Predict Outcomes of Antidepressant Treatment in Adults With Depression: A Prespecified Secondary Analysis of a Randomized Clinical Trial. Rajpurkar P; Yang J; Dass N; Vale V; Keller AS; Irvin J; Taylor Z; Basu S; Ng A; Williams LM JAMA Netw Open; 2020 Jun; 3(6):e206653. PubMed ID: 32568399 [TBL] [Abstract][Full Text] [Related]
10. Response trajectories during escitalopram treatment of patients with major depressive disorder. Nunez JJ; Liu YS; Cao B; Frey BN; Ho K; Milev R; Müller DJ; Rotzinger S; Soares CN; Taylor VH; Uher R; Kennedy SH; Lam RW Psychiatry Res; 2023 Sep; 327():115361. PubMed ID: 37523890 [TBL] [Abstract][Full Text] [Related]
11. The analysis of network structure among the depressive symptoms in a clinical sample of children and adolescents. Kim KM; Kim H; Kim D; Kim JW Asian J Psychiatr; 2021 Aug; 62():102748. PubMed ID: 34243062 [TBL] [Abstract][Full Text] [Related]
12. Measures of Connectivity and Dorsolateral Prefrontal Cortex Volumes and Depressive Symptoms Following Treatment With Selective Serotonin Reuptake Inhibitors in Adolescents. Lee KH; Shin J; Lee J; Yoo JH; Kim JW; Brent DA JAMA Netw Open; 2023 Aug; 6(8):e2327331. PubMed ID: 37540512 [TBL] [Abstract][Full Text] [Related]
13. Early reduction in irritability is associated with improved outcomes among youth with depression: Findings from the AMOD study. Mohamed AK; Croarkin PE; Jha MK; Vande Voort JL J Affect Disord; 2023 Mar; 324():77-81. PubMed ID: 36549343 [TBL] [Abstract][Full Text] [Related]
14. Transcranial Magnetic Stimulation Markers of Antidepressant Treatment in Adolescents With Major Depressive Disorder. Doruk Camsari D; Lewis CP; Sonmez AI; Nandakumar AL; Gresbrink MA; Daskalakis ZJ; Croarkin PE Int J Neuropsychopharmacol; 2019 Jul; 22(7):435-444. PubMed ID: 31095686 [TBL] [Abstract][Full Text] [Related]
15. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study. Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208 [TBL] [Abstract][Full Text] [Related]
16. Pre-treatment factor structures of the Montgomery and Åsberg Depression Rating scale as predictors of response to escitalopram in Indian patients with non-psychotic major depressive disorder. Basu A; Chadda R; Sood M; Rizwan SA Asian J Psychiatr; 2017 Aug; 28():154-159. PubMed ID: 28784374 [TBL] [Abstract][Full Text] [Related]
17. Escitalopram: in the treatment of major depressive disorder in adolescent patients. Yang LP; Scott LJ Paediatr Drugs; 2010 Jun; 12(3):155-63. PubMed ID: 20481645 [TBL] [Abstract][Full Text] [Related]
18. Sleep Disturbance, Irritability, and Response to Lurasidone Treatment in Children and Adolescents with Bipolar Depression. Singh MK; Siu C; Tocco M; Pikalov A; Loebel A Curr Neuropharmacol; 2023; 21(6):1393-1404. PubMed ID: 36173066 [TBL] [Abstract][Full Text] [Related]
19. [Safety and efficacy of oral escitalopram as continuation treatment of intravenous citalopram, in patients with major depressive disorder--the navigade switch study]. Schmitt L; Arbus C; Tonnoir B Encephale; 2006; 32(2 Pt 1):270-7. PubMed ID: 16910629 [TBL] [Abstract][Full Text] [Related]
20. Escitalopram in the treatment of adolescent depression: a randomized, double-blind, placebo-controlled extension trial. Findling RL; Robb A; Bose A J Child Adolesc Psychopharmacol; 2013 Sep; 23(7):468-80. PubMed ID: 24041408 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]